Healthcare Outlook

Omeprazole delayed-release capsules in combination with other medications are used to eliminate H. pylori, a bacteria causing ulcers and prevent the development of new ulcers in people with a history of ulcer formation of the small intestine. Prescription omeprazole is also used to treat higher acid producing stomach conditions such as Zollinger-Ellison syndrome in adults. According to the survey by Clinical Gastroenterology and Hepatology, 2012, ZES occurs in about one in every 1 million people, and is more common among men 30 to 50 years old.

Market Dynamics

Increasing prevalence of acid related diseases (ARDs) including gastroesophageal reflux disease (GERD) is a major factor driving omeprazole market growth. According to the research survey conducted by Florida Hospitals, 2015, pregnant women are at a higher risk of acid reflux, with an estimated 25% pregnant women experiencing the symptoms. The survey further stated that about 20% of people with acid reflux are at a higher risk of developing gastroesophageal reflux disease (GERD). Furthermore, increase in H.pylori infection and NSAID associated gastric and duodenal ulcers are expected to bolster market growth in the near future.

For In-Depth Review | Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/2380

Also, launch of low-cost generic versions of omeprazole is expected to fuel market growth. For instance, in 2016, Dr. Reddy’s launched generic version to Zegerid capsules (omeprazole/sodium bicarbonate) for short-term treatment of stomach and duodenal ulcers, erosive esophagitis and heartburn associated with gastroesophageal reflux disease (GERD).

Increasing prevalence of peptic ulcers is expected to propel omeprazole market growth

Increasing prevalence of duodenal ulcers is expected to propel growth of the omeprazole market. According to a survey by Virtual Medical Center, 2016, peptic ulcer is the most common disease occurring in about 10-15% of the global population at a time. It is common in men and more common in elderly people. The survey further stated that duodenal ulcers are four times more common than gastric ulcers.

Increasing prevalence of H.pylori associated infection and favorable pricing policies to bolster the market growth

North America is expected to hold a dominant position in the global omeprazole market. This is owing to increasing number of people affected by H.pylori infection, which in turn is expected to increase the risk of gastric and duodenal ulcers. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Health Information Center, 2014, about 30 to 40 percent of people in the U.S. suffer from the H. pylori infection, thus increasing the risk of duodenal and gastric development.

Key Players

Major players operating in the global omeprazole market include, Astrazeneca Plc., Sandoz, Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s Laboratories, Inc., Impax Laboratories, Inc., Perrigo Company Plc, Santarus, Inc., Watson laboratories, Inc., and Lek Pharmaceuticals d.d.

Detailed Segmentation:

Global Omeprazole Market, By Dosage Form:

Capsule

Powder

Tablet

Global Omeprazole Market, By Indication:

Duodenal Ulcer

Gastric Ulcer

Gastroesophageal Reflux Disease (GERD)

Erosive Esophagitis

Others

Browse Complete Research Report @ https://www.coherentmarketinsights.com/market-insight/omeprazole-market-2380

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com